Head-to-Head: which MS drug works better in daily life?
NCT ID NCT07566988
First seen May 09, 2026 · Last updated May 16, 2026 · Updated 2 times
Summary
This study looked at over 2,600 people with multiple sclerosis to compare two drugs, Kesimpta and Ocrevus, using real-world insurance data. The goal was to see which one better prevents relapses and reduces healthcare visits and costs. Both drugs are already approved for MS, and this research helps doctors understand their effectiveness outside of controlled clinical trials.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis
East Hanover, New Jersey, 07936, United States
Conditions
Explore the condition pages connected to this study.